<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01214889</url>
  </required_header>
  <id_info>
    <org_study_id>E2I49</org_study_id>
    <secondary_id>U1111-1115-6381</secondary_id>
    <nct_id>NCT01214889</nct_id>
  </id_info>
  <brief_title>Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants.</brief_title>
  <official_title>Immunogenicity and Safety of the Sanofi Pasteur's DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM™) Versus Sanofi Pasteur's DTacP-IPV Combined Vaccine (TETRAXIM™) Given Simultaneously at Separate Sites With PRP~T Conjugate Vaccine (ACTHIB™) as a Three-dose Primary Vaccination at 2, 4 and 6 Months of Age in South Korean Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to assess the immunogenicity and safety of PENTAXIM™ combined vaccine
      versus TETRAXIM™ vaccine to support registration of PENTAXIM™ in South Korea.

      Primary Objective:

      To demonstrate the non-inferiority in terms of seroprotection rates (Diphtheria, Tetanus,
      Polio types 1, 2 and 3, Polyribosyl Ribitol Phosphate [PRP]) and vaccine response rates to
      acellular Pertussis antigens of sanofi pasteur's PENTAXIM™ vaccine versus sanofi pasteur's
      TETRAXIM™ and Act (Haemophilus influenzae type b) HIB™ vaccines, one month after the
      three-dose primary vaccination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All participants will receive three primary doses of their assigned study the vaccine, on
      Days 0, 60, and 120. They will be assessed for immunogenicity on Day 0 before vaccination and
      Day 150 post-vaccination. Safety will be assessed for all participants throughout the study,
      up to Day 157.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non-inferiority in terms of seroprotection rates (Diphtheria, Tetanus, Polio types 1, 2 and 3, Polyribosyl Ribitol Phosphate conjugated to Tetanus protein) of PENTAXIM™ Vaccine to the Tetraxim™ and PRP~T conjugate (Act-HIB™) vaccines.</measure>
    <time_frame>1 month post-dose 3 vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Information regarding the safety (in terms of solicited injection site and systemic reactions) of PENTAXIM™ vaccine.</measure>
    <time_frame>Day 0 up to Day 157</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">370</enrollment>
  <condition>Diphtheria</condition>
  <condition>Tetanus</condition>
  <condition>Pertussis</condition>
  <condition>Poliomyelitis</condition>
  <condition>Haemophilus Influenzae Type B</condition>
  <arm_group>
    <arm_group_label>Study Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of DTacP-IPV//PRP T combined vaccine (PENTAXIM™) at age 2, 4 and 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Study Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive a dose of DTacP IPV combined vaccine (TETRAXIM™) and PRP-T vaccine (ActHIB™) at 2, 4, and 6 months of age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PENTAXIM™: DTacP IPV//PRP~T combined vaccine</intervention_name>
    <description>0.5 mL, intramuscular</description>
    <arm_group_label>Study Group A</arm_group_label>
    <other_name>PENTAXIM™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TETRAXIM™: DTacP IPV combined vaccine and ActHIB™: PRP tetanus conjugate vaccine</intervention_name>
    <description>0.5 mL of each vaccine; intramuscular</description>
    <arm_group_label>Study Group B</arm_group_label>
    <other_name>TETRAXIM™</other_name>
    <other_name>ActHIB™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 2 months (56 to 70 days) inclusive on the day of inclusion

          -  Born at full term of pregnancy (≥ 37 weeks) and with a birth weight ≥ 2.5 kg

          -  Informed consent form signed by the parent(s) or other legal representative

          -  Able to attend all scheduled visits and to comply with all trial procedures

        Exclusion Criteria:

          -  Participation in another clinical trial in the 4 weeks preceding the trial inclusion

          -  Planned participation in another clinical trial during the present trial period

          -  Congenital or acquired immunodeficiency, immunosuppressive therapy such as long term
             systemic corticosteroids therapy

          -  Systemic hypersensitivity to any of the vaccine components or history of a life
             threatening reaction to the trial vaccine or a vaccine containing the same substances

          -  Chronic illness at a stage that could interfere with trial conduct or completion

          -  Blood or blood derived products received in the past or current or planned
             administration during the trial (including immunoglobulins).

          -  Any vaccination in the 3 weeks preceding the first trial vaccination.

          -  History of diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type
             b infection (confirmed either clinically, serologically or microbiologically).

          -  Clinical or known serological evidence of systemic illness including Hepatitis B,
             Hepatitis C and/or Human Immunodeficiency Virus (HIV) infection

          -  Previous vaccination against the diphtheria, tetanus, pertussis, poliomyelitis
             diseases or Haemophilus influenzae type b infection with the trial vaccine or another
             vaccine.

          -  Thrombocytopenia or a bleeding disorder contraindicating intramuscular vaccination

          -  History of/current major neurological diseases or seizures.

          -  Febrile illness (axillary temperature ≥ 38ºC) or acute illness on the day of
             inclusion.

          -  Known family history of congenital or genetic immuno-deficiency.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>56 Days</minimum_age>
    <maximum_age>70 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur SA</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Daejeon</city>
        <zip>301723</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gyeionggi do</city>
        <zip>411706</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gyeonggi-do</city>
        <zip>420767</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gyeonggi-do</city>
        <zip>420818</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Incheon</city>
        <zip>400700</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Incheon</city>
        <zip>403720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Incheon</city>
        <zip>405760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>110744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>130702</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>132703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>133792</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>135710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>137701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>158710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofiaventis.com</url>
  </link>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2010</study_first_submitted>
  <study_first_submitted_qc>October 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2010</study_first_posted>
  <last_update_submitted>April 13, 2012</last_update_submitted>
  <last_update_submitted_qc>April 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diphtheria</keyword>
  <keyword>Tetanus</keyword>
  <keyword>Pertussis</keyword>
  <keyword>Haemophilus influenzae type B</keyword>
  <keyword>Poliomyelitis</keyword>
  <keyword>PENTAXIM™</keyword>
  <keyword>TETRAXIM™</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Whooping Cough</mesh_term>
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
    <mesh_term>Poliomyelitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

